Identification and Semi -Quantification of ER/PR Proteins Expression

Applied Spectral Imaging

Status: Completed

Conditions: Breast Cancer

Treatments: Procedure: Cancer patients; Procedure: Breast Cancer patient

Study type: Observational

Funder types: Industry

Identifiers

NCT02654431

ASI-ER/PR-IHC

Details and patient eligibility

About

The purpose of the study is the identification and quantification of proteins expression level in breast cancer tissues.

The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classifying ER/PR IHC stained samples.

Full description

The anti ER/PR Kit is a semi-quantitative immunohistochemical (IHC) assay to identify the progesterone (PR) and estrogen (ER) expressions in formalin-fixed, paraffin-embedded human breast cancer tissue specimens. Results from the ER/PR test is indicated as an aid in the assessment of the hormones status of breast cancer patients. While the ER/PR kit provides the antibodies that offer direct visualization and semi-quantification of the protein expression through a brightfield microscope, the GenASIs GoPath system is designed to complement the routine workflow of the pathologist in the review of immunohistochemically stained histologic slides.

Enrollment: 350 patients

Sex: Female

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women having breast cancer

Exclusion criteria

• others

Trial design

350 participants in 3 patient groups

Breast Cancer patients

Description:

Breast cancer patients

Treatment:

Procedure: Breast Cancer patient

Procedure: Cancer patients

women with breast cancer

Description:

women with breast cancer

Treatment:

Procedure: Breast Cancer patient

Procedure: Cancer patients

Cancer patients

Description:

Cancer patients

Treatment:

Procedure: Breast Cancer patient

Procedure: Cancer patients